Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Innate Immuno’s MS trial drug gets global spotlight

For Immediate Release

Innate Immuno’s MS trial drug gets global spotlight

Auckland, NZ, October 12 2012: Research details of a drug that may help people with secondary multiple sclerosis (MS), developed by New Zealand biopharmaceutical company Innate Immunotherapeutics, is being highlighted at the world’s biggest annual gathering of MS specialists and pharmaceutical companies, ECTRIMS, in Lyon, France today.

Innate’s study co-principal investigator, Dr Alison Luckey, talk about the result of 1B/2A trials of its drug MIS416 in the late breaking news section of ECTRIMS. More than 6,000 people attend the conference.

Simon Wilkinson, chief executive of Innate Immunotherapeutics, says results of the Phase 1/2 clinical trial have shown MIS416 to be well tolerated and identified a clinical dose for further evaluation.

“For most international clinicians and researchers into MS this will be the first time they will heard about our drug, that it has been in early stage trials and most importantly that early results are encouraging,” he says. “We are grateful for the support of the United States National MS Society at ECTRIMS, especially for the credibility and validation of our programme the society’s support provides.”

Neurologist Professor Tim Anderson, co-principal investigator for the study, announced in June this year that preliminary data indicate MIS416 is safe and well tolerated. The MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients.

During the dose confirmation portion of the study, eight of 10 patients with secondary progressive MS treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms.

Innate Immunotherapeutics plans to enroll MS suffers in 2013 for a 12 month Phase 2B study to investigate the sustainability of the improvements in seen in the first study.

“We plan to conduct most of the next study in Australia, to take advantage of that country’s greater patient availability,” Mr Wilkinson says. “If we can get appropriate local support it would be good to also have trial sites in New Zealand too. Right now we are working hard during the next few months to raise around US$10 million that we need to run that longer phase 2B study. We are certainly hopeful our exposure at ECTRIMS will help us with that.”

In addition to the support of the United States-based National Multiple Sclerosis Society, Innate has had financial support from the New Zealand Ministry of Science and Innovation. It is also collaborating with New Zealand and US universities that specialise in oncology research, to conduct preclinical studies of MIS416 in other applications, including treatment vaccines for a number of different cancers.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Air NZ Wine Awards: Victory For Villa Maria As Pinot Noir Thrills

It was a night to remember as Villa Maria Estate picked up one of the highest accolades of the evening, the O-I New Zealand Reserve Wine of the Show Trophy, at the 28th Air New Zealand Wine Awards. The Villa Maria Single Vineyard Southern Clays Marlborough ... More>>

ALSO:

Future Brighter Money: RBNZ Releases New Bank Note Designs

New Zealand’s banknotes are getting brighter and better, with the Reserve Bank today unveiling more vibrant and secure banknote designs which will progressively enter circulation later next year. More>>

ALSO:

Commerce: Supermarket Inquiry Finds No Breaches By Countdown

The Commerce Commission inquiry into anti-competitive behaviour by Countdown supermarkets, alleged by former Labour Party MP Shane Jones, has found nothing to warrant prosecution, although it warns supermarkets to take care in the way they communicate... More>>

ALSO:

Crown Accounts: English Flags ‘Challenge’ To Budget Surplus

Finance Minister Bill English is warning next month’s half yearly fiscal and economic update from the Treasury may not forecast a budget surplus, saying that returning the government’s accounts to surplus in 2015 will be “a challenge”, given the decline in commodity prices and weak global inflation. More>>

ALSO:

March 2015: Netflix To Launch In Australia And New Zealand

World’s Leading Internet Television Network to Offer Original Series, Movies, Documentaries, Stand-Up Comedy Specials and TV Shows for Low Monthly Price More>>

ALSO:

Price Of Cheese (Is Up): Dairy Product Prices Fall To Five-Year Low

Dairy product prices fell in the latest GlobalDairyTrade auction to the lowest level in more than five years, led by declines in rennet casein and skim milk powder. More>>

ALSO:

Gordon Campbell: On The Australians Scoring Trade Points Against Us With The Chinese

It hasn’t been a great year for Trade Minister Tim Groser... To top it off, Australia has just signed a FTA with China that has far better provisions on dairy exports than what New Zealand currently enjoys in our own FTA with China. More>>

ALSO:

Iwi & Local Consultation: Oil And Gas Block Offer 2015 Begins

Energy and Resources Minister Simon Bridges today announced the start of the Block Offer 2015 process for awarding oil and gas exploration permits. More>>

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news